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Beeson evokes memories of Yale
With all due respect to the “Iron 
’Terns” and their consider-
able accomplishments [“Six 
Degrees of Paul Beeson,” Yale 
Medicine, Spring 2015], Paul 
Beeson, M.D., attracted and 
inspired many outstanding 
classes of house officers during 
his 13-year tenure as chairman 
(pardon the old designation) 
of the Department of Medicine 
at Yale. He was aided in this 
task by an outstanding faculty: 
Gerald Klatskin, M.D., in liver 
diseases, Philip Bondy, M.D., in 
endocrinology, Stuart Finch, 
M.D., in hematology, Howard 
Spiro, M.D., in gastroenterol-
ogy, Allan Goodyear, M.D., in 
cardiology, and Elisha Atkins, 
M.D., his partner in the study of 
fever, just to name a few. I was 
privileged to meet Dr. Beeson 
when I was but an intern in 
surgery at Yale in the 1953-54 
academic year. I had recently 
returned from a brief conva-
lescence in Florida following a 
nine-week hospitalization for 
what was known then as serum 
hepatitis contracted from a 
needle stick. Dr. Beeson was 
facing an abdominal operation 
and, thinking ahead, wondered 
whether convalescing in Florida 
was a good idea, and he asked 
me! I didn’t think he knew I 
even existed, let alone that I 
had been ill. Our very pleasant 
professional and even personal 
relationship continued through 
my residency in surgery and 
my years on the faculty before 
I moved to Stanford in March 
1965 at the invitation of Bob 
Chase. Dr. Beeson was planning 
a sabbatical year at Stanford 
to begin in July 1965, and I 
was doing a little house and 
school searching for him and 
his family. In May of that year, 
I received a letter from Dr. 
Beeson saying that he would 
not be coming to Stanford 
because he had accepted the 
offer to become Nuffield Chair 
of Medicine at Oxford—as 
understandable a reason as 
one could imagine for such a 
change in plans.
Paul Beeson was a towering 
figure in medicine, at once highly 
accomplished, quietly stimulat-
ing, approachable, and modest. 
Maybe someone has constructed 
a family tree of his trainees 
similar to the “Iron ’Terns.” If 
not, someone should. That might 
even be a suitable project for a 
Yale School of Medicine thesis or 
a talk at a meeting of the Yale 
Historical Society.
James B. D. Mark, M.D., HS ’54 
Professor of Cardiothoracic  
Surgery, Emeritus 
Stanford University School of 
Medicine
Having fond memories of Paul 
Beeson, M.D., upon receiving 
the recent Yale Medicine, I open 
immediately to the double-page 
photograph of the Iron ’Terns. 
Imagine my surprise and delight 
in seeing myself 50 years 
younger in the group. I’m the 
funny-looking guy with glasses 
standing in the front row,  
second from the right—between 
John Burke (#14) and Harold 
Federman (#15). I was an assis-
tant resident, having graduated 
from Yale School of Medicine in 
1963, and having been an intern 
in 1963-64. For the record, 
while not as academically dis-
tinguished as many of my fellow 
interns, I subsequently was in 
the private practice of internal 
medicine for 30 years in a small 
Vermont city, served as presi-
dent of the medical staff at the 
Rutland Regional Medical Center, 
and was a clinical instructor  
in medicine at the University  
of Vermont. 
David F. Cross, M.D. ’63, HS ’64 
Glade Hill, Va.
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  Memory has a  
role in almost every  
 biological process
I T  H A S B E E N SA I D that our memories make us who we are. We turn  
our memories into stories with meaning and wisdom, and share them  
in the hope that others can learn from them. Our memories take  
different forms—some fleeting and others hardwired into our brains, 
available for quick recall. Our immune system remembers foreign 
invaders in order to stop them before they do damage, and our cells 
remember whether their DNA has suffered damage and undergone 
repairs. Yale Medicine spoke with Dean Robert J. Alpern, M.D., about 
the importance of memory in medicine, science, and beyond.
Why is the study of memory so important? The study of memory is important because 
of its role in almost every biological process. We think of the brain as the location of 
memory, but almost every cellular and molecular process in the body uses memory 
to increase its efficiency. However, understanding memory in the brain is uniquely 
important because this form of memory defines who we are. We now live in an age 
where we survive cancer and heart disease, but later many become impaired by dis-
eases such as Alzheimer’s.
How will Yale’s new Alzheimer’s Disease Research Unit advance the study of disease 
and, hopefully, lead to better diagnosis and treatment? When we performed stra-
tegic planning 10 years ago, one of the highest research priorities identified was 
neurodegenerative diseases, and in response the Center for Cellular Neuroscience, 
Neurodegeneration and Repair (CNNR) was formed. The success of CNNR contributed 
to our ability to become an Alzheimer’s unit. We still don’t completely understand 
what causes amyloid protein or tau to accumulate in the brain, but we hope to use the 
Alzheimer’s Disease Research Unit to advance our understanding and develop new 
therapies to address this disease. 
What aspect of memory do you find most interesting? The ability of the brain to create its 
own memory. People have memories that actually never happened or may not have 
happened exactly as remembered. If you tell a story enough times, it starts to become 
a true memory, triggering all of the biological mechanisms associated with long-term 
memory. This fascinates me. 
What should readers remember from this issue of Yale Medicine? They should remember 
the beauty of biology. While simple memory occurs in the simplest of organisms, the 
complex memory performed by our brains required a long time to evolve and defines 
the human species and other high-level species. To preserve these memories is one of 





















W H E N T H E ROB E RT WO OD JOH N S ON F OU N DAT ION 
(RWJF) ended its longstanding Clinical Scholars program 
last year, it was a loss not only for the Yale community 
but for the city of New Haven as well. Since the pro-
gram’s inception more than 40 years ago, scholars have 
worked on projects designed to address health inequities 
and improve health care throughout the city. The more 
than 160 Yale scholars who have graduated from the pro-
gram since 1974 have had a strong impact on New Haven 
through community-based research that assessed a range 
of topics, including the availability of healthy foods in  
a New Haven neighborhood without a supermarket,  
HIV/AIDS status, gun violence, immigrant and refugee 
health, and access to health care for the homeless.
 Team-based science is focus  
of new clinician scholars program
»
Cary Gross has led the 
transition to a new clini-
cian scholars program, 
which for the first time 
teams residents with 
students from the School 
of Nursing.
“I’ve never been part of a training 
program that is blessed with so 
much loyalty, appreciation, and 
dedication among the alumni, the 
faculty, and the institutional and 
community partners,” said Cary 
P. Gross, M.D., professor of medi-
cine and co-director of the RWJF 
program at Yale. “That is why we 
simply had to find a way to con-
tinue training the next genera-
tion of scholars who will lead our 
efforts to improve the health care 
system and enhance the health of 
yalemedicine.yale.edu4
individual patients, our commu-
nities, and the nation.”
Though RWJF decided last 
year to stop funding the clini-
cal scholars program, the four 
host sites—the University of 
California, Los Angeles; the 
University of Michigan; the 
University of Pennsylvania; 
chronicle
and Yale—took up the mantle to 
begin a new independent fellow-
ship in a spirit similar to that of 
the original program.
“Forging ahead was an 
unspoken mandate,” said Gross, 
as the four sites decided that the 
work of the program is not yet 
complete. “When we discussed 
the challenge with leadership 
at Yale, the question was never 
whether to continue train-
ing scholars; it was how to do 
it. Dean [Robert J.] Alpern has 
been incredibly supportive.” The 
new National Clinician Scholars 
Program (NCSP) will share many 
features with the original pro-
gram, but the consortium made 
key changes in order to adapt 
to a new element of the chang-
ing health care landscape—an 
increased emphasis on team-
based approaches to research as 
well as clinical care. As a result, 
the NCSP will train doctoral-
level nurse-scientists side by 
side with physicians.
In clinical practice, such 
team-based approaches as 
patient-centered medical homes 
are increasingly common, and 
they bring together physicians, 
nurses, physician associates, 
and others to collaborate with 
patients in making decisions 
about care. “Team-based care 
is a common and effective part 
of our health care system,” said 
Gross, who is leading the plan-
ning of the NCSP at Yale. The 
decision to include nurse- 
scholars in the NCSP builds 
upon the interdisciplinary  
framework of the RWJF program, 
which trained physicians from 
various specialties together, 
including internists, surgeons, 
pediatricians, and others.
“No profession can do it all 
themselves, and we each have 
important roles to play in the 
delivery of health care across the 
health continuum,” said Margaret 
Grey, Dr.P.H., M.S.W. ’76, dean 
of the Yale School of Nursing. 
“The more we educate people in 
silos—whether for clinical prac-
tice, or clinical research, or health 
services research—the less likely 
it is that they will work col-
laboratively when they get out 
in the real world.” In addition, 
she noted, postdoctoral training 
slots for nurses are limited, and 
the NCSP will provide a much-
needed avenue for nurses who 
seek to combine clinical work 
with research.
The new two-year program 
will select approximately five 
physician- and nurse-scholars 
per year to complete coursework 
together at Yale, sharing men-
tors from across the professions. 
NCSP scholars will lead their 
own policy-relevant research 
projects, guided by faculty and 
community partners. They will 
also learn the value of collabora-
tion as they participate as team 
members in their peers’ projects.
Scholars will be encouraged 
to translate their research dis-
coveries into real-world change 
by working with community 
partners, health care providers, 
or government agencies to 
ensure that they are asking 
questions that are important 
to stakeholders and that the 
results of their studies will have 
an impact. Scholars will build 
upon collaborations that have 
grown with the existing clini-
cal scholars program, which 
has included such partners as 
the VA Connecticut Healthcare 
System, Yale-New Haven 
Hospital, Columbus House, 
Integrated Refugee & Immigrant 
Services, Project Access of New 
Haven, and New Haven Family 
Alliance, among others. “One 
of the hallmark features of the 
scholars program has been the 
link between scholarship and 
action,” said Gross. “We place 
a great emphasis on teaching 
scholars not just how to do 
research but also how to instill 
change, working either from 
within the health care system or 
from outside the system.”
While the NCSP is aimed 
at early-career, post-training 
physician- and nurse-scientists, 
the trend toward interpro-
fessional education, or IPE, 
increasingly appears at all lev-
els of medical education. The 
Liaison Committee on Medical 
Education, an accreditation 
body, has established a new 
standard that requires medi-
cal schools to include collab-
orative education as part of 
their core curricula. At Yale, 
when the School of Medicine 
redesigned its curriculum, 
Eve R. Colson, M.D., profes-
sor of pediatrics, joined with 
colleagues from the School 
of Nursing and the Physician 
















Alumnus Vivek Murthy, 
M.D. ’03, M.B.A. ’03, 
returns to Yale as the U.S. 
Surgeon General.
Lessons from the 
Ebola crisis at this year’s 
Global Health Day.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 
on our home page at 
yalemedicine.yale.edu.
the health care system. For the 85 
percent of inmates who received 
regular care in prison for such 
chronic conditions as diabetes 
and hypertension, one of their 
fi rst stops upon release is the 
emergency department.
“To me,” said Wang, an associ-
ate professor of medicine, “that 
was an incredibly ineffi  cient way 
to run a health care system. It was 
frustrating. It was inhumane.”
In 2005, during her last 
year of residency, she began 
the Transitions Clinic Network 
(TCN) to help recently released 
inmates adjust to life outside 
prison by providing access to 
health care. What began as 
one clinic in San Francisco has 
IPE component to the course 
she leads, the Longitudinal 
Clinical Experience. Th at pro-
gram places medical students 
in community-based clinical 
settings from their fi rst days of 
medical school. Now, fi rst-year 
nursing and physician associate 
students are also included, 
said Colson.
Having the NCSP at Yale will 
contribute to IPE’s goal of col-
laboration, Colson said, by pro-
viding students with role models 
for how to work together across 
professions. “How many hours 
does a basketball team prac-
tice together before they play a 
game?” said Colson. “Whereas 
in medicine, all of us who take 
care of patients, we don’t really 
practice together. We just play 
the game.”
Gross said the four-member 
consortium is eager to get 
started on the NCSP, which will 
accept up to 25 scholars across 
all sites for the program’s fi rst 
cohort in 2016, with the hope 
that new institutions will sub-
sequently join the founding sites. 
“It was really exciting to see 
how the leadership at the four 
university sites really banded 
together,” Gross said, “and 
realized that the whole would 
be greater than the sum of our 
parts if we continued to work 
together. Th is really shows that 
the benefi ts of working in teams 
applies to large universities, just 




Health and the justice 
system
As an intern on an emergency 
department rotation at the 
University of California, San 
Francisco, in 2003, Emily Wang, 
M.D., was shocked to learn 
that many of her patients had 
recently left prison, some within 
the past few days. Equally 
shocking, she realized, was 
that for many of these patients, 
prison offered them their fi rst 
access to health care.
Th e U.S. Supreme Court 
has ruled that health care for 
inmates is required by the 
Eighth Amendment to the U.S. 
Constitution. Upon an inmate’s 
release, however, the mandate 
disappears and signifi cant bar-
riers to care arise. Most newly 
released inmates have no primary 
care providers and no insurance, 
and do not know how to navigate 
chronicle
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Hospital. Each of these transfers 
carries a degree of risk. Health 
care providers and hospital 
administrators have long studied 
the “handoff,” when a new doc-
tor takes over patient care during 
a shift change or a move from 
one service to another and cru-
cial information can fall through 
the cracks. But now a team of 
doctors and providers is taking a 
broader look at those transitions 
to anticipate problems and find 
ways to mitigate them.
Over much of the past year, 
Alana Rosenberg, M.P.H., has 
spent many hours in the hospital 
standing in hallways, at nurses’ 
stations and, in the emergency 
department, watching residents, 
attending physicians, nurses, 
business associates, and patients. 
With an anthropologist’s eye, 
Rosenberg, a research associ-
ate in internal medicine, is part 
of a team that observed those 
moments when a patient enters 
the hospital, moves from one 
part of the hospital to another, 
or leaves the hospital for home, 
hospice, or a care facility. Then 
the team interviewed the people 
involved—doctors, nurses, 
staff, and patients. Part of the 
impetus for the study comes 
from the Institute of Medicine’s 
1999 report, To Err Is Human: 
Building a Safer Health System. 
The report, which estimated 
that between 44,000 and 98,000 
people die each year because of 
preventable medical errors, con-
vinced clinicians and investiga-
tors that new studies of patient 
safety were needed.
inmates who saw a primary 
care physician within a month 
of release had fewer emergency 
department visits and hospi-
talizations than those who did 
not. “It seems like a place where 
the smallest sorts of adjustments 
can make the biggest gains,” 
Wang said.
With funding from the Yale 
Center for Clinical Investigation 
and the Patient-Centered 
Outcomes Research Institute, 
Wang and her colleagues are 
developing a Web-based plat-
form that will disseminate 
to TCN clinics, patients, and 
community stakeholders the 
data she has collected through 
nationwide studies of TCN 
patients. TCN has also formed 
a partnership with Yale Law 
School to help TCN patients in 
New Haven address legal needs 
related to housing, employment, 
and other social issues related 
to the health of former inmates. 
“There won’t be a singular solu-
tion,” Wang said, to addressing 
the criminal justice system’s 





Every year Yale-New Haven 
Hospital (YNHH) admits more 
than 50,000 patients. Once in 
the hospital, patients may move, 
for example, from the emergency 
department to intensive care or 
from medicine to Smilow Cancer 
grown into 15 clinics in seven 
states and Puerto Rico, with 
plans to expand. TCN has two 
clinics in New Haven, at the Yale 
Primary Care Center and the 
Cornell Scott-Hill Health Center.
This is how it works: TCN 
community health workers, all 
of them former inmates, meet 
former prisoners on their release. 
They help patients get insurance, 
see a primary care physician, and 
connect with services to help 
with housing and employment.
Kathleen F. Maurer, M.D., 
MPH ’85, director of Health and 
Addiction Services and medi-
cal director of the Connecticut 
Department of Correction, views 
the peer advocate aspect of 
TCN as crucial. “These patients 
relate to their peers in a way 
they couldn’t relate to a physi-
cian,” she said. In Connecticut, 
inmate patients are released with 
a four-week supply of medica-
tion and get help connecting to 
Medicaid, often their only source 
of insurance. Maurer said that 
the Department of Correction 
relies on TCN to help them stay 
connected to health care.
The criminal justice system 
has an enormous scope: 63 mil-
lion Americans have criminal 
records, and 13 million move in 
and out of correctional facili-
ties each year. It’s clear from 
medical literature, Wang said, 
that poor health can prevent 
former inmates from getting a 
job, and employment is one of 
the most important factors in 
helping them stay out of prison. 
















“Patients are moving through 
the health system at a very fast 
pace, and the technology that 
we have is increasingly complex 
and sophisticated,” said Sarwat 
Chaudhry, M.D., FW ’05, associ-
ate professor of medicine. “Th e 
diagnostic evaluations that 
we’re doing and the data that 
we as clinicians are juggling 
are mind-boggling compared 
to 20 or 30 years ago. You really 
need multiple checks and sys-
tems in place to make sure that 
things are happening the way 
they’re supposed to.”
While past efforts have fol-
lowed the traditional route of 
devising an intervention, test-
ing it, and analyzing the results, 
the Center for Healthcare 
Innovation, Redesign and 
Learning (CHIRAL) is taking 
a new approach. Funded by a 
grant from the U.S. Department 
of Health & Human Services’ 
Agency for Healthcare Research 
and Quality (AHRQ), CHIRAL 
starts with an in-depth prob-
lem analysis of patient safety 
in three areas, and then works 
with clinicians and experts from 
such industries as aviation and 
engineering to devise solutions.
“We have a lot to learn from 
other industries that are ahead of 
medicine, where you just count 
on the individual remember-
ing to do the right thing,” said 
Chaudhry, principal investigator 
for the part of the project that 
involves transfers within YNHH. 
Th e other projects, headed by 
Marc Auerbach, M.D., assistant 
professor of pediatrics, and Grace 
Y. Jenq, M.D., FW ’04, associate 
professor of medicine (geriatrics), 
will look at patients entering 
the Yale-New Haven Children’s 
Hospital emergency depart-
ment, and patients moving out 
of YNHH into skilled nursing 
facilities. “Clinical deterioration 
can happen during transport 
because you’re not monitored 
like you were on a fl oor,” said 
Beth Hodshon, J.D., M.P.H., R.N., 
project director for CHIRAL.
CHIRAL, a joint venture 
between the School of Medicine 
and YNHH, was among the fi rst 
centers funded by the AHRQ ini-
tiative. “We’re one of the largest 
health systems in the country,” 
Chaudhry noted. “We have the 
medical school and a world-class 
hospital and health system, but 
bringing together expertise from 
both sides and both perspectives 
was an important opportunity.”
Following a year of ethno-
graphic observations for each 
of the three projects, CHIRAL 
looked at such specifi c issues 
as communication, handoffs, 
and data fl ow. Team members 
observed and interviewed 
everyone involved in transi-
tions—health care providers, 
ancillary staff, business associ-
ates, and patients—while the 
data team studied information 
collected in Epic, the electronic 
medical record. In August, the 
team met with national and 
local experts to study inter-
ventions that might be effec-
tive. Unlike traditional studies 
that end after an intervention 
is tested and the results are 
reported, the interventions 
devised by CHIRAL will be 
continuously designed, imple-
mented, and tested in a process 
that will end only when a solu-
tion is shown to be effective. 
“Protocols can be put in place, 
but it’s everyone’s reaction 
[to how things are done] that 




Welcome to the Class 
of 2019! A new class 
dons the white coat.
A clinic founded by 
Yale med students ex-
pands its reach in the 
wake of Nepal’s devas-
tating earthquake.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 
on our home page at 
yalemedicine.yale.edu.
As part of a months-long study, 
Alana Rosenberg interviewed 
health care workers and patients 
to fi nd out what works and what 
doesn’t work during transition 
points in hospital stays.
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  POCKET-SIZED  
 DIVERSITY
It might be time to toss those clunky 
paper field guides. Researchers from 
Yale and the University of Florida just 
unveiled a new smartphone app called 
Map of Life to track plant and animal 
species around the world. The app is 
based on a global scientific database 
that launched in 2012 to catalog bio-
diversity. Users can not only see an 
informative list and photographs of 
all the species in their area, but also 
contribute their personal observations. 
“This vast information, personalized 
for where we are, can change the way 
we identify and learn about the things 
we see when traveling, hiking in the 
woods, or stepping in our own back-
yard,” said Walter Jetz, M.Sc., D.Phil., 
associate professor of ecology and 
evolutionary biology, and the visionary 
behind Map of Life. To download the 
app, visit http://mol.org/mobile.
Men with detectable HIV infec-
tions need less alcohol to feel 
“buzzed” compared to uninfected 
men, according to recent work 
by researchers from Yale and the 
Veterans Health Administration. 
Survey responses from over 2,600 
men in the Veterans Aging Cohort 
Study, 607 with detectable HIV 
infections and 871 with suppressed 
HIV, showed that men with detect-
able infections need a quarter of a 
drink less than their counterparts to 
feel the effects of alcohol. “All else 
equal, people who have HIV infec-
tion have a lower tolerance for alco-
hol than similar people without HIV 
infection,” said Amy C. Justice, M.D. 
’88, M.Sc., Ph.D., professor of medi-
cine and public health and senior 
author on the study. The study was 
published in April in the journal  
AIDS and Behavior.
  THE BUZZ  
 ABOUT HIV
  GENE-EDITING  
 CYSTIC FIBROSIS
Lassa virus, which can cause deadly 
hemorrhagic fever similar to Ebola, and 
was first described at Yale in 1969, kills 
approximately 5,000 people a year, 
according to the Centers for Disease 
Control and Prevention—but now it’s 
helping in the fight against brain can-
cer. VSV, a virus related to rabies, pre-
viously showed promise getting past 
the blood-brain barrier and targeting 
cancer cells, but it could also cause a 
potentially lethal brain infection. Yale 
and Harvard researchers used viruses 
in which VSV proteins were replaced 
with portions of the Lassa virus, creat-
ing a safe “chimeric” virus that suc-
cessfully destroyed brain tumors in 
mice without causing disease, accord-
ing to a study published in the April 
issue of Journal of Virology. “We are 
very excited about these new chimeric 
viruses that contain genes from multi-
ple viruses. They work well in targeting 
cancer in animals, and we hope that 
they will also work effectively if tested 
in humans,” said Tony van den Pol, 
Ph.D. ’77, professor of neurosurgery 
and the study’s senior author.
Researchers have engineered a novel 
way to correct one of the genetic 
mutations that cause cystic fibrosis, a 
lethal disorder of the lungs and diges-
tive system, as reported in the April 
issue of Nature Communications. Using 
gene-editing technology, the team 
combined healthy DNA with synthetic 
molecules called peptide nucleic acids 
that trigger repair near the cystic 
fibrosis mutation and then delivered 
the molecules in mice via biodegrad-
able nanoparticles. They also tested 
the treatment on human cell cultures. 
“The percentage of cells in humans and 
in mice that we were able to edit the 
CFTR mutation in using these nanopar-
ticles containing triplex forming 
peptide nucleic acids was higher than 
has been previously reported with any 
gene-editing technology,” said Marie E. 
Egan, M.D., professor of pediatrics and 
the study’s senior author. “This is step 
one in a long process. The technology 
could be used as a way to fix the basic 
genetic defect in cystic fibrosis.”






































































a collection of recent  
scientific findings
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MEMORY FASCINATES US. We’ve created a genre of literature we call 
memoir. We take our memories and toy with them until they form a 
coherent narrative, one that makes sense of our lives and allows us to live 
with things we might like to forget. We’re embarrassed when we have 
a “Rick Perry” moment and can’t retrieve from our brain something that 
should be on the tip of our tongue. We recall vividly a night from 10 years 
back but can’t remember what we discussed at last week’s staff meeting. 
And we know that our memories are not set in stone, and that we can be 
induced to “remember” events that never happened.
Neuroscience tells us that memories are patterns of synaptic connections 
among the billions of neurons in our brain. Where our memories are stored 
depends on what kind of memories they are. Is this phone number destined 
to be a short-term memory, staying in our brain just long enough to dial? 
Is this memory procedural, involving motor skills like tying a shoelace or 
strumming a guitar? Is it traumatic or emotional, requiring the services 
of the amygdala to process? Is it a semantic memory, the kind of fact that 
keeps us up at night while we cram for a test? The brain has a spot for each 
of them, but we still don’t know where all of our memories reside.
This issue of Yale Medicine is devoted to these notions of memory and 
different ways to understand them. We asked doctors who write for their 
perspectives on how and why we turn our memories into stories. Doctors tell 
us why Alzheimer disease, which erodes our memories, is one of the most 
feared disorders in the country.
As Oscar Wilde put it, “Memory is the diary we all carry about with us.”
yalemedicine.yale.edu10
 Your entire brain is memory— 
and your memory is who you are
What is memory? 
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How circuits of neurons become 
the narratives of our lives.
By Karen Zusi Meriel Jane Waissman Illustrations
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instructs Marvin Chun, Ph.D., professor 
of psychology and neurobiology. “Now, 
if I test you a week later by showing  
you a picture of a lollipop and asking, 
‘Did you ever see this?,’ you’re probably 
going to say yes even though you just 
imagined it.”
  “Close your eyes and 
 think of a lollipop,”
What is memory?
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Memory is a story. The entirety of our lives, real and 
imagined, is grounded in memories of learning, think-
ing, and doing, making our memories inextricably 
linked to our identities. Every time you recall some-
thing, a series of neurons lights up your brain, covering 
it like a patterned spider web of energy. Remembering 
the details of where you were, whom you were with, 
and what an event looked or sounded like causes your 
brain to activate and occasionally modify this pattern. 
Like a children’s game of “Telephone,” details can get 
altered or lost in translation; the brain doesn’t operate 
like a perfect videotape. But its changeability ensures 
that we can create and store memories in vast num-
bers of adaptive neural connections, constantly adding 
threads to the tapestries of our persons.
where memories start
There’s a lot that scientists still don’t know about how 
we form and store memories, but the beginnings of one 
are easy to trace. All memories start with perception. 
Through thinking, touching, hearing, seeing, tast-
ing, and smelling, we process our surroundings and 
things that affect us. “Today I walked into the door and 
bumped my elbow,” offers Jessica Cardin, Ph.D., assis-
tant professor of neurobiology, as an example. “You have 
to have a context for that memory. You have to see that 
you’re in your office.” In the brain, the cortex receives 
all of this information from various systems and fun-
nels it into the hippocampus, which creates associations 
throughout the neural network. But from there, every-
thing depends on what type of memory is being formed. 
Muscle memory—learning how to play the piano 
or ride a bike—uses a different part of the brain than 
remembering how you celebrated your birthday last 
year. Spilling coffee on yourself during a meeting is 
recalled differently from how to use a knife and fork, 
which is different from remembering the dates you 
studied for a history test the night before. Some memo-
ries are constantly reinforced by our environments and 
therefore made stronger—it’s easier to forget where you 
placed your keys last night than it is to forget the route 
from your home to the office.
Mistakes, however, often occur in the perceptual 
phase. “People are terrible observers most of the time,” 
says Cardin, who studies the interplay between neurons 
in both healthy and diseased brains. Eyewitness testi-
mony is notoriously fallible due to missing or imagined 
details. Psychologists have also conducted experiments 
in which a subject takes a sheet of paper from some-
one behind a desk, who then bends down to retrieve 
something. A different person behind the desk stands 
up—and the subject rarely notices. The experiment isn’t 
meant to embarrass people, or to point out how little 
they remember about the people they just met, but 
rather as an example of how they prioritize where they 
direct their attention. In these cases, were the clients 
later asked to recall what the person behind the desk 
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looked like, odds are they would offer only general 
details: gender, or perhaps race.
For items or events to which we do pay atten-
tion, we build chemical connections to consolidate a 
memory. Compared to the number of neurons in the 
average brain, a single person will have a seemingly 
unlimited number of experiences. “You can’t assign 
one memory per neuron,” says Cardin. Even with 100 
billion neurons, there simply aren’t enough. Instead, 
rather than selecting one cell to hold all memories of 
a family member, we create a pattern involving only a 
portion of the available neurons, combining them in 
different numbers and sequences.
a discrete “thing” in  the br ain
Researchers once envisioned memory as a discrete 
“thing” in the brain, but now they search for these pat-
terns of replay that indicate information being recalled. 
Your brain can ignite the pattern for recall in multiple 
ways, along any part. According to Cardin, smell is one 
of the best ways to activate a memory. The nerves that 
react to and process smells in the air connect directly 
to the limbic system—which includes the hippocam-
pus. We can also ignite patterns of recall by envision-
ing specific details or places. If someone asked you to 
remember something about your childhood, you might 
start with an image of your elementary school building 
or your first pet and build from there.
When we reactivate such a neural recall pattern, it 
becomes malleable. It’s unlikely that anyone would 
believe they actually saw a lollipop since reading Chun’s 
instructions, but that might change a week later if sub-
jects were unaware of the test’s purpose. Memory is 
like a wax seal, Chun says: First, you heat up the wax to 
press an imprint into it, which then solidifies. But the 
act of retrieval warms up the wax again. “That malle-
ability—the fact that it becomes reprogrammable—that 
physical fact is what allows memories to become stron-
ger or weaker,” says Chun. “There’s no such thing as 
reading out exactly what was encoded. It all involves 
opening the files, making the wax warm again, because 
we’re just dealing with proteins in the brain.” 
False memories can be created by something as sim-
ple as a leading question. “You can do it experimentally 
by having people witness an event,” says Cardin. A 
subject might observe a brown-haired person bumping 
into someone, with an experimenter afterwards ask-
ing the witness what time the blond person bumped 
into the other. A week or two later, when asked to 
describe the event, the witness is more likely to say 
that a blond-haired person bumped into someone. The 
immediate follow-up by the experimenter is crucial; 
when recalling the event later, the witness’s brain acti-
vates the pattern of neurons and therefore heats up the 
wax again, allowing the memory to be modified by the 
suggestive question. 
Change occurs to some types of memory more easily 
than others. Memory of our personal timeline, referred 
to as “episodic memory” or memory with a date and 
time stamp, is most susceptible to alteration or decay. 
The memory of what you gave a friend for a birthday 
or who attended the party is less resilient than the 
memory of what purpose a chair serves. Similarly, for-
getting that the sky is usually blue or that a zebra is 
striped would be unlikely without some type of brain 
damage. These learned memories, ingrained factual 
information outside our personal experiences, are 
categorized as “semantic memory.” Psychologists still 
debate whether the brain handles the information in 
one system or two and how much reinforcement the 
brain needs before a fact becomes part of semantic 
memory, but no one argues that a distinction exists.
tr auma as a research tool
Traumatic brain damage and neural disease provide 
critical information about what memory is and how it 
works. Some of the brain’s memory systems are partic-
ularly robust. While episodic memory is often the first 
to go, skill memory—the eponymous “muscle memory” 
—is one of the most resilient. Even amnesiacs don’t 
forget how to walk. Those who have difficulty form-
ing new personal memories can still learn new motor 
skills, including complex tasks like writing backwards 
on a mirror. The brain stores skill memory in a differ-
ent region from plain information.
When humans do forget things, the process may 
occur in a few different ways. The act of trying to 
remember is akin to searching for something on a 
computer hard drive or in a messy room. If the com-
puter files are organized, or the room has been recently 
What is memory?
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cleaned, the search is easier—but with time and 
entropy, finding things becomes difficult. “Memory 
is the exact same thing,” says Chun. “Sometimes, it’s 
hard to find because of all the other stuff.” Whether 
memory patterns, if formed through proper attention, 
can ever be truly “deleted” from our brains is still an 
open question in psychology. However, they decay and 
can be overwritten by more important information. 
This notion of forgetting or lost memories has long 
been a source of fascination for pop culture. Movies 
across all genres deal with the topic: The Notebook 
for Alzheimer disease; Memento or 50 First Dates for 
What is memory?
anterograde amnesia, in which the main characters 
cannot form new memories; The Bourne Identity 
and Eternal Sunshine of the Spotless Mind for a more 
science-fiction take on lost memories. “We don’t really 
understand forgetting that well,” says Chun, but he 
points out that an abnormal rate of memory loss is one 
of the most debilitating situations in which patients 
can find themselves: “It robs you of who you are and 
how people relate to you.”
Clinically, forgetting as a process receives signifi-
cant research attention. Even though memory pat-
terns are spread throughout the brain, conditions 
like Alzheimer disease hit memory the hardest of all 
the brain functions. “What we can do to stave off and 
understand that disease is probably our most pressing 
challenge,” says Chun. “The more you can understand 
memory and the more you can map it onto the brain, 
and the more you can understand when it goes bad and 
when you can preserve it—what all memory research-
ers do is helpful for that effort.”
But our brains have also created forgetting as an 
adaptive function, and researchers are harnessing it 
to treat other disorders. With chemicals that block 
neurotransmitters, scientists are researching memory 
alteration as a potential therapy for post-traumatic 
stress disorder, drug addiction, delusions, and phobias. 
By activating a memory and then using an agent that 
weakens connections in the brain, researchers may be 
able to remove the emotional attachment or craving 
that accompanies the memory pattern and stop it from 
being reinforced. 
Memory as a higher brain function defines who we 
are. We rely on our memories for experience, wisdom, 
relationships, flexibility, and any ability to learn. Even 
in Greek mythology, the Muses—goddesses of inspira-
tion and knowledge in the arts and sciences—were 
daughters of Mnemosyne, the goddess of memory. But 
when our identities are predicated on a temporal con-
tinuity, what does it mean when it turns out we’re not 
exact documentaries but some flavor of creative, narra-
tive film? Our brains simply do the best they can—the 
rest is up to us. /yale medicine
Karen Zusi was Yale Medicine’s writing intern in 2015.
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Healthy humans are born with billions of infection-fighting 
machines called T cells. We need so many because a 
T cell exists for virtually every type of virus, bacterium, or 
parasite. T cells respond to foreign intruders by replicating 
like mad to generate an army of these defenders, including 
killer T cells. As the infection clears, millions of those T cells 
die off. Only 5 to 10 percent remain in the blood, poised to 
attack like a boxer anticipating a familiar foe’s first punch. 
These are memory T cells.
“Your immune system gets imprinted physically with 
cells that are generated during the first infection,” said  
Susan Kaech, Ph.D., associate professor of immunobiology  
and a Howard Hughes Medical Institute early career sci-
entist. This is why vaccines are so crucial, she said. The 
immune system remembers the infectious agent so it can 
ward off infections immediately, rather than letting nature 
run its slower (and sometimes fatal) course.
But how do T cells become memory T cells? Scientists 
had long assumed that the process was random and largely 
governed by external forces. Research over the past decade, 
however, suggests that certain T cells may be more intrinsi-
cally fit to become a long-lived memory T cell. During a 
viral infection, some T cells express a receptor designed to 
detect a cytokine called interleukin-7, and those cells live to 
fight future infections. Most other T cells do not express that 
receptor, and they don’t survive.
Yet research also suggests that environmental forces 
might be at work. The more inflammation T cells are 
exposed to, for example, the greater their chances of dif-
ferentiating into killer T cells that can help clear the present 
infection. This exposure, however, also makes them more 
likely to die after an infection. In contrast, T cells only mildly 
exposed to inflammation or to anti-inflammatory signals 
are more likely to develop into memory T cells. 
How such diversity of T cell fates arises remains a puzzle. 
Are T cells born as either memory or terminal T cells?  
“I think that would be kind of scary. It would be like pre-
determining the fate of a person while they were still in the 
womb,” Kaech said, noting that infection is unpredictable, 
never giving advance warning of which pathogen might 
strike, when or where it comes from, and how much you’ll 
be exposed to. In the face of such random events, the im-
mune system must remain pliable. “You don’t know what 
someone will become before they are born; and similarly, 
you wouldn’t want your immune system deciding if a T cell 
was going to live or die before it has even seen the patho-














A T cell’s fate
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On their journey through the brain, our 
memories pass through the hippocampus, a 
temporary transit hub. Where they go next 
depends on whether your brain is recording 
the capitals of the 50 states, your reaction to 
the latest Seth Rogen movie, or the shock of 
witnessing a traffic accident.
For every memory, the brain creates a new 
circuit of neurons, or alters or strengthens 
an existing circuit. And each memory has 
a context—it’s encoded in the brain based 
on meaning and association. Long-term 
memories fall into two types, declara-
tive and nondeclarative. Under declara-
tive memories—which are encoded by 
the hippocampus, entorhinal cortex, and 
perirhinal cortex, but consolidated and 
stored in other parts of the brain—come 
episodic memories. Episodic memories are 
our personal experiences, including the 
emotional charge of those experiences: the 
day I started med school … the time I spilled 
coffee on my suit just before a job interview 
… the first time I laid eyes on the love of my 
life. These personal memories end up in 
the medial temporal lobe and neocortex. 
Anything emotional or traumatic involves 
the amygdala. Semantic memories are the 
things outside of our personal experience 
that we learn, say, from textbooks. What’s 
the capital of Estonia? When was the Battle 
of Waterloo? Can you recite pi to 10 digits? 
These types of memory reside in the lateral 
and anterior temporal cortex and the pre-
frontal cortex.
Nondeclarative memory lets us remem-
ber how to ride a bicycle, strum a guitar, or 
hammer a nail. These procedural memories 
  A memory’s  journey
are encoded and stored by the cerebellum, 
putamen, caudate nucleus, and motor cortex.
Short-term memory, or working memory, 
has been likened to a scratch pad where 
we jot down a phone number. Unless we 
make an effort to retain that number, it will 
disappear. The central executive part of the 
prefrontal cortex handles these types of 
memories. Ever wonder why we break up 
phone numbers and credit card numbers? 
That’s “chunking,” breaking a long number 
into chunks, which allows us to increase our 
short-term memory capacity.
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There are things we just 
remember, and the things we 
work at remembering, like 
studying for a test in microbiol-
ogy or American history. What 
year did Lincoln deliver the 
Gettysburg address? What’s the 
difference between DNA and 
RNA? These learned facts and 
figures outside of our personal 
experience become part of 
our semantic memory, but not 
everything in our semantic 
memory comes from text-
books. These memories can be 
the facts common to our cul-
ture, like the name of our state 
capital or the current president, 
and include other facts we 
acquire over a lifetime. Trying 
to cram all these things into our 
brain the night before a test is 
probably the worst thing we 
can do. Research has shown 
that we need to sleep in order 
to consolidate our memories.
“Mechanical memories,” which 
we now call procedural memo-
ries, were first observed in 
1804. This is knowing how to 
do things. These are the skills 
we acquire and never forget, 
like riding a bicycle. If you play 
an instrument it seems like 
the muscles in your fingers 
remember, too, and know ex-
actly where to strike that key or 
form that chord. Without even 
thinking, we know, in a given 
song, which note comes next. 
Procedural memory allows the 
muscles in a quarterback’s or 
pitcher’s arm to throw the ball 
with accuracy, and without 
even thinking about it. Like-
wise, hammering a nail is one 
of those skills that stays with 
you. Your muscles just know. 
Why do we write to-do lists? 
Even our working memory has 
its limits. We use it to hold on 
to something for as long as we 
need it and no longer—usually 
just a few seconds. What’s the 
number of that takeout Chinese 
place? What’s that email ad-
dress? In the 1950s, it was pos-
ited that our capacity to hold 
on to information is limited to a 
handful of “chunks.” That’s why 
we break up long series of dig-
its like our phone numbers or 
social security numbers. And, 
as we age, working memory 
is among the functions most 
likely to decline.
There are things in our lives, like 
slipping on the sidewalk and 
breaking an arm, that remain 
as episodic memories—the 
stories of our lives. Somehow 
we organize these memories 
into coherent narratives with 
a beginning, middle, and end. 
Along with the broken arm, 
we’ll remember where we were 
coming from, where we were 
going, whether we were dis-
tracted by our cell phone, the 
ice on the sidewalk, the mo-
ment of slipping, the realization 
that we were going to fall and 
that it was going to hurt. But 
episodic memories can also be 
pleasant—a Labor Day barbe-
cue at the beach with friends, 
the conversation, the sound of 
the surf, and the food. Through 
these memories we travel back 





















In the typical adult human, there are 206 bones, at least 
700 named muscles, 78 organs, 12 pairs of cranial nerves 
and 32 pairs of spinal nerves, and a formidable array of 
named veins and arteries, all of which, during medical 
training, a budding doctor will be asked to commit to 
memory. That, of course, is only the beginning. There are 
an untold number of procedures to memorize, as well as 
a host of diseases—currently more than 30,000—to cram 
into the cerebral cortex, and when the training process is 
complete, assuming it is ever really done, physicians are 
expected throughout their careers to dig into their brains’ 
hard drives and retrieve relevant information quickly, ef-
fortlessly, and flawlessly.
But in the modern technological era, when tablets 
and smartphones are as much a part of a doctor’s regalia 
as a white coat and a stethoscope—Yale students receive 
iPads when they enter medical school—does it still make 
sense to engage in all that memory work? Neurobiologist 
Michael Schwartz, Ph.D., associate dean for curriculum, 
said that’s a question worth exploring. With the explosion 
of knowledge and the ease with which it can be accessed 
by technology, he said, we need to be more thoughtful 
about which facts need to be in the memory for immedi-
ate application. “Memorization takes up far too much 
cognitive bandwidth when we should be focusing more 
on the application of knowledge. Technology now gives 
us the opportunity to access all that information instan-
taneously, and this is changing the way we train doctors 
and practice medicine.”
Internist Auguste H. Fortin VI, M.D., M.P.H., believes 
that it’s mostly a change for the better. “Most of medical 
education has revolved around filling up the empty vessel 
with facts, but with scientific knowledge growing explo-
sively, no one can possibly keep it all in mind,” said Fortin, 
who teaches communication skills and always has his 
iPhone handy in the exam room.
While there had been fears that computers of any 
variety would be seen by patients as intrusive, those wor-
ries haven’t played out. “I’ll tell patients when I’m looking 
something up that I’m almost positive about the condition, 
but I just want to double-check and make sure my recol-
lection is correct,” Fortin explained. “And I show them 
what I’m doing so they know I’m not texting or checking 
my shopping list. The iDevice has become a partner, a way 
to ensure quality control and improve patient care.”
The fact that Fortin is less reliant on memory is a big 
plus since he freely admits that his memory is less than 
photographic. “I remember sometimes having to invent 
a pretense to leave an examination room so I could go 
back into the office to look something up in a book,” he 
explained. “There was a bit of shame in this—I didn’t want 
a patient to know that I didn’t have it all in my head.”
That shame is gone, but while Fortin may not have 
the entirety of Harrison’s Principles of Internal Medicine 
What’s in a doctor’s brain, 
and what’s online
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at his cognitive fingertips, he has all of his specialty’s 
typical procedures, to say nothing of an impressive array 
of facts, at his disposal. This doesn’t include the proper 
dose of every medication imaginable—these are readily 
available online—but Fortin and his fellow internists know 
by heart the proper flow of a patient encounter and the 
skills needed to draw out a patient to effect a differential 
diagnosis. “You memorize the more common situations, 
like if you see someone with chest pains who has these 
particular qualities, you might be looking at diagnosis A, B, 
C, or D,” he said. “You vaguely recall that there could also 
be E or F, but you’d have to look up the specifics.”
The emphasis on methodology rather than memoriza-
tion is where medical training is heading. “We’re actively 
trying to determine the base level of knowledge a physi-
cian absolutely requires to do the job, especially in an 
emergency when you simply don’t have time to look 
things up,” said Schwartz. “Figuring this out is one of the 
primary challenges of modern medical education.”
But if the jury is still out on precisely what a doctor 
needs to memorize, the proper habits of mind are clear in 
the iAge—or any age. “One of our central tasks as teachers 
is to instill in students the value of looking things up and, 
of course, teaching them where to obtain the highest and 
most reputable quality information out there. This is where 
medical research librarians are worth their weight in gold,” 
said Fortin. “You have to be confident in what you know, 
as well as confident that you can find out what you don’t 
know or can’t quite remember. But above all else, you 
can’t forget that the patient—not the iPhone, tablet, or any 
other iTool—is your focus. These devices are just another 
















The things we remember become 
tales with morals and meanings.
By Jenny Blair Sophie Casson Illustrations
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Thomas P. Duffy, M.D., was asked to verify 
the suicide of a young nursing student.
 As chief resident  
on the arduous Osler  
 service at Johns
 Hopkins in the 1960s,
Our memories, our stories
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Alone, he entered her room and found the student 
upright in bed, dressed in lace, stained with vomit, 
dead from an overdose of sedatives. A supervisor soon 
joined him and asked Duffy to fill out death forms and 
search the room for anything embarrassing. He found 
a risqué snapshot of a happy young man wearing only 
combat boots.
Minutes later, Duffy hurried to grand rounds. 
Determined to maintain equanimity, he chose not to 
discuss or even think further about the young wom-
an’s death or his role in sanitizing it.
Years later, as a professor of medicine at Yale, Duffy 
sat down to write an article for the journal The Pharos 
about his Hopkins years. As he thought back, the 
memory of this incident returned full force. For the 
first time, he mentally revisited the young woman’s 
deathbed, and he included her story in the article. His 
failure to acknowledge the young woman’s death had 
been callous, he wrote, while his need to put it out of 
his mind illustrated a system that was unaware of the 
emotional disruption that encounters with tragedy 
could trigger in young doctors. The program’s pyramid 
system winnowed half of each residency class annually 
while demanding what Duffy wrote was an “almost 
superhuman effort” and a “conspiracy of silence” 
about traumatic experiences. For the house staff, he 
wrote, this training amounted to “self-torture.”
Duffy believes it is important to share such experi-
ences. “If one does not address moments like that,  
at some point in the future one pays the toll,” he said.  
“It comes back to haunt you.”
Denial and machismo hardly make for healthy souls. 
Yet studies of interventions for post-traumatic stress 
disorder (PTSD) show that recounting a traumatic 
incident right away can sometimes mean worse stress 
symptoms later, too. Stories that bring healing and 
insight can take time to assemble from the raw mate-
rial of the memory. Decades, even.
Narrative underlies most, if not all, of our attempts to 
make sense of the world. Yet the links between memory 
and stories are many and complex. Memory is less like 
a set of index cards and more like a set of systems that 
direct decisions, many unconscious, about how to 
reconstruct and interpret events in the past. From such 
decisions, stories arise. How these processes take place, 
how they heal or harm, how faithfully they affect real-
ity, are by no means straightforward questions.
To create compelling stories aimed at other read-
ers, fiction writers draw upon their own experiences. 
But too much reliance on memory can paradoxically 
weaken prose, according to novelist Bret Anthony 
Johnston, who urges his writing students to buck the 
advice “Write what you know.” By all means, he writes 
in a 2011 essay for The Atlantic, set stories in a familiar 
setting and festoon them with details from memories. 
But then route the plot away from memory. Let char-
acters do things you’ve never done. Fiction’s narrative 
and emotional integrity can and should trump the lit-
eral truth of what happened.
“Stories aren’t about actions. Stories are, unto them-
selves, actions,” Johnston writes.
Medical professionals who want to write accounts 
of their patients are faced with a practical and ethical 
concern: how to conceal patients’ identities and protect 
their privacy. Anna B. Reisman, M.D., associate profes-
sor of medicine and co-director of a writing workshop 
for residents, recommends that residents (and any 
health care professional writing about patients) either 
remove enough detail to hide patients’ identities or 
ask their permission, which is also fraught with ethi-
cal issues. Ideally, one does both; another option is to 
go beyond simple de-identification. Write a story, she 
advised in The Atlantic in February, free from depen-
dence on the facts of what happened. To Reisman, 
fictionalizing a medical history not only is the more 
clearly ethical option, but it can also yield truths inde-
pendent of literal accuracy. “Sometimes, the truth can 
emerge more clearly—and more kindly—through the 
prism of fiction,” she writes.
The mind seems to think so, too, as memory rou-
tinely obliges the present by rewriting the past. 
Eyewitness testimony is so malleable, its underlying 
memories so subject to suggestion and prone to distor-
tion, that it can wrongly convict a defendant. The 1980s 
recovered-memory movement sent many innocents 
to prison after their accusers came to believe that they 
had been abused as children, often encouraged by 
well-meaning therapists to tell stories of rape or Satan 
worship. Researchers now understand that false mem-




  Anna Reisman // Read more on page 44
 “You read a great novel and you really empathize 
  with the characters, you get into their heads, 
you see things from their perspective. 
 What better training to be a good doctor than to be 
  able to imagine what a patient is going through! ’’
In everyday life, too, simply recalling and retelling 
memories can alter them. The act of retrieving  
and reconsolidating a memory seems to render it  
susceptible to change, as if we could reread only 
while highlighting and crossing out. This effect is so 
strong that researchers are looking to tweak it for 
better PTSD treatments.
“In order to incorporate [memories] into the story, 
what was vague has to become concretized. So no 
question, we polish them,” Duffy said. “[Knowing] 
how it all played out, now the memories are refracted 
through a different prism.”
Stories can heal, a truth well-known to Annita P. 
Sawyer, Ph.D. ’81, assistant clinical professor of psy-
chiatry and a practicing psychotherapist. In 1960, as  
an adolescent traumatized by family abuse, Sawyer 
was misdiagnosed with schizophrenia, hospitalized, 
and subjected to shock treatments that erased much  
of her memory. She built a successful life, keeping  
the hospitalization a secret. But in 2001, she decided  
to read her own medical records from that long- 
ago time.
Disturbing memories rushed back, shaking her 
deeply. Clinical experience told her that she must have 
had PTSD back then, not schizophrenia. Compelled  
to rethink her own identity, she realized she had a 
story to tell.
During the decade that followed, as Sawyer read, 
remembered, and wrote, an ingrained feeling of dis-
connection from daily life gradually disappeared.  
So did her lifelong shyness. Her life story retold  
lost its frightening energy, and she felt whole.  
She published Smoking Cigarettes, Eating Glass:  
A Psychologist’s Memoir last spring.
Whether in therapy or in memoir, Sawyer says, 
constructing a true story allows another person to  
hold your experience, helping transform “incho-
ate, churning” memories into something orderly and 
coherent. (Her patients’ lives are so much like novels, 
she says, that she has no trouble remembering all the 
characters from their stories.)
Even if this story doesn’t perfectly correspond to 
reality, even if it’s filled with the kind of ugliness her 
book’s title suggests, a story based on truth can restore 
a fragmented sense of self.
“People don’t have to have prettiness,” Sawyer said. 
“People don’t need a story to be pretty; they need it to 
make sense.” /yale medicine
Jenny Blair, M.D. ’04, is a frequent contributor to Yale Medicine.














Fish oil, ginkgo tea, dark chocolate, and periwinkle extract 
have all been touted as brain enhancers, along with count-
less infomercial pills. But do any of them preserve memory as 
we age? Says one Yale neurologist—well, forget about it.
“Dietary supplements have pretty much failed,” says 
Jaime Grutzendler, M.D., associate professor of neurology 
and neurobiology and director of the Center for Experimental 
Neuroimaging. “Vitamin B12, vitamin E, vitamin C—all the 
studies that have been done so far have not shown any long-
term benefits.”
For Grutzendler, Alzheimer disease and other brain condi-
tions are the ultimate challenge. His lab studies different 
pathologies in the brain using real-time cellular imaging; like 
early astronomers gathering information by watching the 
night sky, he enters research with no agenda. He just wants 
to find out how things work. “We don’t have a preconceived 
notion of what the system should do or how it should dete-
riorate,” he says. With these methods, Grutzendler’s work has 
shed light on theories about how we fall into cognitive decline.
The causes of cognitive decline are nearly as varied as the 
supplements sold to prevent it. In his office, where Pollock-
like images of fluorescent brain cells decorate the walls,  
Grutzendler points to a series of images on his computer 
screen. They depict structures in the brain associated with 
dementia, primarily the plaques famously found in Alzheimer 
patients and the lesser-known but no less common neuro-
fibrillary tangles. These tangles are built-up proteins inside 
neurons, as opposed to plaques, which form outside the cells 
and can cover large portions of the brain. They both interfere 
with cellular signaling.
Aging itself is associated with plaques and tangles, which 
lead to some degree of cognitive slowing and potential 
memory loss. But they don’t always appear in the same places 
or at the same times. “Aging is complicated,” says Grutzendler. 
“Aging is not one disease. It’s the disease of almost everything, 
like an old car—basically, everything starts to fall apart in some 
way.” Neurologists look at different types of damage in the 
brain that may lead to the same symptoms, just as a dead bat-
tery or a faulty ignition switch both mean a car won’t start.
So, are all humans doomed to some form of cognitive de-
cline if we live long enough? Grutzendler speculates yes—but 
not all hope is lost. Supplements haven’t worked conclusively 
in preventing or slowing dementia, but vascular health—
making sure your circulatory system gets blood to body parts 
that need it—is important at any stage of life. And factors 
affecting vascular health aren’t so difficult to pin down.
Uncontrolled diabetes, obesity, hypertension, and 
smoking are all associated with damage to small blood ves-
sels in the brain. When these vessels are affected, less blood 
makes it to the neurons, weakening their connections. Sci-
entists haven’t yet demonstrated a bulletproof connection 
to cognitive decline, but Grutzendler concludes that these 
are serious risk factors.
Sleep is another factor believed to affect cognitive health, 
though those links have not been fully demonstrated. The 
best science, however, still tells us that sleep, exercise, good 
nutrition, and control of such risk factors as smoking and 
high blood pressure are some of the keys to a healthy life-
style—and a healthy brain.
—Karen Zusi
Can ginkgo tea preserve our memories?
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Misplaced keys and forgotten appointments 
are among the episodic memories that are 
lost to Alzheimer disease. Yale clinicians 
and scientists are looking for new ways to 
predict the disease and find a cure.
By Ashley P. Taylor Matthew Daley Illustrations
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that Chris H. van Dyck, M.D., first noticed 
something different about his grandfather. 
The retired Presbyterian minister, then 83, 
was at the head of the table making a speech 
to old friends. “He looked like Granddad there, 
doing his thing. And he was reasonably  
coherent,” van Dyck, then about 20 years old, 
recalls. Until he’d finished the speech. “I went 
over to him and said, ‘Hello, Granddad,’  
and he looked at me and said, ‘Who are you?’ ” 
 It was at his maternal 
grandparents’ 50th  
 wedding anniversary
The first things to go
yalemedicine.yale.edu34
That was the summer of 1975, and van Dyck’s grand-
father was in the beginning stages of Alzheimer disease, 
an illness that would later claim both of his maternal 
grandparents, and which van Dyck, a geriatric psychia-
trist, would study as the director of Yale’s Alzheimer’s 
Disease Research Unit. 
Alzheimer disease is characterized by a gradual 
loss of what, arguably, makes people who they are: 
their memories. It starts with innocent forgetfulness. 
“Usually the first thing to go is episodic memory,” says 
Arash Salardini, M.D., co-director of Yale’s Memory 
Disorders Clinic, referring to memories with specific 
contexts in space and time. “Based on that, you can see 
what sort of memories usually go first. People misplace 
things. They forget appointments.” People first lose 
the ability to form new memories, while long-term 
memories—the sort van Dyck’s grandfather was prob-
ably recounting at the anniversary—are more resilient. 
As the disease progresses, people start to lose executive 
functions: the ability to make and carry out plans. They 
lose interest in hobbies; they can no longer use the 
phone, drive a car, or balance a checkbook. Eventually, 
they can no longer attend to their own basic needs 
and become dependent on others. In the United States, 
Alzheimer disease ranks high on the list of diseases 
people most fear.
After van Dyck’s grandfather became ill, van Dyck 
says, his mother bought her parents a house near her 
home in northern Vermont so that she could take care 
of them. As the grandfather’s dementia progressed, 
van Dyck’s mother ended up hiring nearly 24-hour 
live-in care. Almost immediately after his grandfather 
died, van Dyck says, his grandmother began to show 
signs of memory loss, too; she died of Alzheimer 
disease a few years later. Then his mother’s second 
husband, van Dyck’s stepfather, got the disease, and 
his mother cared for him until his death. “She was 
immersed in Alzheimer disease,” van Dyck says. His 
mother, now 89, shows no signs of dementia.
Though he believes his choice to focus on Alzheimer 
disease was in part intellectual, van Dyck feels that 
his family history also nudged him in that direction. 
“Seeing my mother do heroic work caring for these 
people was impressive, and showed what that was like 
for families and the need for treatments.”
a disease that def ies  diagnosis
In the past, Alzheimer disease could be definitively diag-
nosed only upon autopsy. Doctors observed two kinds of 
brain pathologies: large plaques of a protein called beta 
amyloid crowding the spaces outside neurons, and inside 
them, what are called neurofibrillary tangles of another 
protein, tau. An accurate clinical diagnosis relied on the 
results of memory and neurological tests and ruling out 
other potential causes of dementia.
Van Dyck began utilizing neuroimaging to study 
the aging brain. He and Yale colleagues (including 
Richard E. Carson, Ph.D., director of the Yale PET 
Center) were among the first to adapt Single-Photon 
Emission Computed Tomography (SPECT) and positron 
emission tomography (PET) to visualize molecules 
in the brain. In conjunction with the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) of the National 
Institutes of Health, van Dyck and the Alzheimer’s 
Disease Research Unit have helped to evaluate PET 
imaging methods to visualize pathological changes in 
the brain linked to Alzheimer disease.
In the past 10 years, the ADNI consortium, along 
with other research teams, has demonstrated that PET 
imaging could be used to visualize beta amyloid in 
the brains of patients with Alzheimer disease and that 
markers of beta amyloid could even be seen in people 
at high risk for the disease before the onset of symp-
toms. Based on this work, amyloid PET scans are now 
approved for use in the diagnosis of Alzheimer disease.
For Salardini, PET scanning is an important diag-
nostic tool, particularly when trying to distinguish 
Alzheimer disease from other types of dementia. These 
brain scans have also brought new understanding 
of the disease itself. Alzheimer disease’s hallmark 
amyloid plaques, researchers have found, accumulate 
decades before symptoms arise. Using PET scans, doc-
tors are getting better at diagnosing Alzheimer disease 
and at determining who is at risk for developing it, 
paving the way toward early interventions.
“You don’t want to treat the disease once the mani-
festations occur and you already have memory loss,” 
says David Hafler, M.D., M.Sc., chair of neurology 
and neurologist-in-chief at Yale-New Haven Hospital. 
Instead, you want to use multiple tests to determine 
who’s at risk and “get patients on treatment before they 
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develop the disease. That’s my vision for what we want 
to do at Yale.”
The glitch, however, is that there is no treatment 
for Alzheimer disease. Yale researchers are trying to 
change that. One clinical trial is testing a drug that 
interferes with a chain of molecular events—triggered 
by beta amyloid—that causes the brain’s neuronal con-
nections to break down. Another is testing whether 
keeping beta amyloid from building up could prevent 
Alzheimer disease. 
hallmarks of alzheimer disease
On a molecular level, Alzheimer disease is characterized 
by the build-up of beta amyloid. Although neuroscien-
tists still aren’t sure what it does, the beta amyloid pep-
tide is part of the healthy brain, where it “gets made and 
rapidly cleared,” explains Stephen M. Strittmatter, M.D., 
Ph.D., Vincent Coates Professor of Neurology, professor of 
neurobiology, and director of the Yale Memory Disorders 
Clinic. In patients with Alzheimer disease, however, beta 
amyloid takes abnormal forms. Fibers clump together 
outside neurons to form the disease’s iconic plaques. 
But it’s a third type of beta amyloid, in which several 
copies of the protein come together to form what are 
called oligomers, that researchers suspect is a culprit in 
Alzheimer disease. Unlike plaques, which are stuck in 
place, the oligomers can float around in the brain, inter-
acting with—and possibly destroying—neurons.
According to research from the Strittmatter lab, 
these beta amyloid oligomers damage synapses—the 
connections between neurons—creating gaps in the 
brain’s communication system. Beta amyloid doesn’t 
damage neurons directly—it starts a domino chain of 
molecular events that shrivels synapses. In mice with 
Alzheimer disease-like symptoms, the Strittmatter lab 
found that using a drug to block one of the proteins in 
this chain, called Fyn kinase, halted the damage and 
allowed both synapses and memory to bounce back. To 
see whether these results carry over to humans, van 
Dyck is testing the drug (saracatinib) in a nationwide 
clinical trial for people with mild symptoms.
Another clinical trial is testing whether an antibody 
that binds to beta amyloid and removes it from the 
body could prevent Alzheimer disease from developing 
in the first place. When tested on Alzheimer disease 
In a vote of confidence, the federal government has des-
ignated Yale as an Alzheimer’s Disease Research Center 
(ADRC)—the medical school will receive funding from the 
National Institutes of Health to compile and analyze data on 
Alzheimer disease patients. The designation comes with a 
five-year grant of more than $1.5 million per year that will 
support many facets of Alzheimer disease research, includ-
ing basic research, collection of clinical data, community 
outreach, and education. The Alzheimer’s Disease Research 
Unit, the Yale Memory Disorders Clinic, and the Dorothy Adler 
Geriatric Assessment Center already provide excellent care to 
Alzheimer disease patients. The grant will allow these groups 
to synthesize their information and resources, thereby 
fostering greater knowledge and advancing potential treat-
ments, says Stephen M. Strittmatter, M.D., Ph.D. (in photo, at 
left), the Vincent Coates Professor of Neurology, professor 
of neurobiology, and director of the Yale Memory Disorders 
Clinic, and principal investigator of the ADRC grant from the 
NIH. He and Chris van Dyck, M.D. (in photo, at right), director 
of the Alzheimer’s Disease Research Unit, co-direct the Yale 
ADRC; Arash Salardini, M.D. (in photo, center), co-director of 
the Memory Disorders Clinic, is its assistant clinical director. 
“The ADRC is composed primarily of people at Yale who were 
previously carrying out separate tasks. Through the new 
center they now work as a team in the sense of meeting to-
gether, sharing ideas and reagents, and coordinating studies 
across the translational research scale,” Strittmatter says.
As the search for a treatment continues, the number  
of Alzheimer disease cases—an estimated 5.3 million  
Americans in 2015, according to the Alzheimer’s Association— 
continues to grow as the population ages.
 Yale designated 



















patients, the overall finding was that the antibody 
(solanezumab) did not work. In a subset of patients 
with mild dementia, however, the drug slowed disease 
progression by about a third, van Dyck says. 
This finding prompted researchers to ask, as van 
Dyck puts it, “What if you go milder than mild, all 
the way to preclinical, presymptomatic? Maybe it’s a 
question of intervening before too much brain dam-
age is done.” The study is testing that hypothesis in 
patients 65 or older who are cognitively normal but 
who have abnormally high levels of beta amyloid, as 
measured by PET scans. In the Anti-Amyloid Treatment 
in Asymptomatic Alzheimer’s Disease (A4) Study, 
which is still enrolling participants, half the patients 
receive monthly intravenous infusions of the drug and 
half receive a placebo. The study is “blind”—neither 
researchers nor participants know who receives the 
drug. At the end of the three-year study, a second PET 
scan for beta amyloid will show whether the drug pre-
vented the protein from accumulating, and “unblinding” 
the results will reveal whether the treatment prevented 
memory loss.
Whether or not removing beta amyloid from the 
brain proves effective in preventing Alzheimer disease, 
it is emerging as a key predictor of risk for the disease 
and crucially, one that shows up long in advance of dis-
ease symptoms. “Almost everybody who has amyloid 
deposition beyond a certain amount will get Alzheimer 
disease, and almost nobody without amyloid deposition 
has Alzheimer disease,” says Salardini, adding that such 
a build-up can begin 20 years before symptoms emerge. 
One day, van Dyck predicts, screening for Alzheimer 
disease using amyloid PET scans may be as routine as 
getting a colonoscopy. “That is the kind of paradigm 
we’re talking about,” he says. “We don’t even want to 
wait until people have lost a bunch of gray matter; we’d 
like to be able to intervene at an earlier stage.” But an 
earlier, more accurate diagnosis will be most valuable 
only when there’s a treatment. Without a treatment, 
there’s no way to act on an earlier diagnosis.
“If we had an intervention that could save people, 
[PET scanning] would just so obviously pay for itself,” 
van Dyck says, noting that insurance doesn’t usu-
ally cover the scans. “The cost of a PET scan would be 
trivial when you compare it to, besides the individual 
costs, just the sheer economic costs to society.”
Strittmatter is optimistic that research will lead  
to possible treatments, and he believes that the part-
nership between the new Alzheimer’s Disease Research 
Unit and the NIH will advance that research.
“I think that research that is going on is opening 
new doors. We have to find out which one will make  
a difference for people.” /yale medicine
Ashley P. Taylor is a freelance writer in Brooklyn, N.Y.
  Arash Salardini //
 “Almost everybody who has amyloid 
deposition beyond a certain amount will get Alzheimer 
  disease, and almost nobody without amyloid 
 deposition has Alzheimer disease. ’’
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yalemedicine.yale.edu38
The New England Patriots would never call a timeout mid-
game to proclaim their status as the weaker team. Animal 
stem cells, however, confess their lesser rank to others all 
the time. In a display of altruism, they send signals to neigh-
boring cells about their levels of stress, oxygen, or nutrition. 
Whatever their status, they serve a common goal—the fitter 
the cell, the more competitive it is in the race to produce 
healthy progeny. 
Ruslan M. Medzhitov, Ph.D., the David W. Wallace Profes-
sor of Immunobiology, and his lab members are studying 
how stem cells become winners or losers in this game of 
reproduction. Stem cells, they have found, appear keen to 
communicate a very technical aspect of their performance: 
their past. A stem cell’s DNA bunched inside chromosomes 
may look as good as new, but this doesn’t stop the cell from 
remembering and divulging its history. If surrounded by 
healthy cells, the cell with a previously repaired genome 
will graciously back out of the race. 
When Medzhitov injected mice with stem cells that 
had been exposed to low-level radiation, histone proteins 
rushed in to “bookmark” damaged regions of DNA. DNA re-
pair genes mended the broken letters and several days later 
turned themselves off. The histone proteins disappeared 
and the stem cell’s genome appeared perfectly normal. But 
a patch job is just that—a patch job. It doesn’t guarantee 
against errors that might occur during the repair. This is why 
previously damaged stem cells declare themselves in the 
first place: they want to pass on only healthy cells to their 
offspring. (Cancer cells, which don’t play fair, never blow 
their cover by disclosing past damage.) 
Medzhitov and his team believe that these memories of 
damage and repair are stored in the form of slight mutations 
in the telomeres, regions of repetitive DNA at the ends of 
chromosomes. “It’s important to understand the selection 
processes that go on in stem cells,” Medzhitov said. A better 
understanding of how everything works could affect bone 
marrow transplant patients, he said. This fragile patient 
population needs lots of healthy stem cells so that their 
blood-making, or hematopoietic, system has a long life 
and is not rife with mutations that could later lead to such 
health problems as cancer. 
—Kathleen Raven














  The history of  
 human monstrosity
In 1834, a Mexican woman 
named Julia Pastrana was 
born with protruding lips 
and thick black hair cover-
ing her face. Her appear-
ance was caused by two rare 
conditions: hypertrichosis, a 
genetic mutation causing her 
hair growth; and gingival 
hyperplasia, an abnormal 
thickening of her gums.  
Both went undiagnosed in 
her time.
Lacking a medical expla-
nation, Pastrana became a 
sideshow oddity, billed as 
the “missing link” between 
humans and apes. She mar-
ried one of her managers and 
had a child with him in 1860, 
but the baby was stillborn 
and Pastrana died shortly 
thereafter. Her story doesn't 
end there—her husband had 
the two bodies stuffed, and 
understanding of these dif-
ferences through history. 
“People think of freak shows 
when they think about 
extreme bodily abnormali-
ties,” said Thompson, “but 
what I wanted to show is 
that there is a scientific way 
of looking at these bodies 
that often undergirds the 
popular culture.”
Thompson and Grafe began 
the exhibit with a pamphlet 
from 1495 about a pair of con-
joined twins. With the inven-
tion of the printing press in 
the mid-1400s, collectors and 
early scientists began publish-
ing catalogues of the natural 
world, including unusual 
humans. “Some of these were 
monsters, people with hairy 
faces or scaly skin, giants, 
dwarfs, or conjoined twins,” 
Thompson said.
Starting in the 18th cen-
tury, the scientific focus 
shifted toward explain-
ing and classifying these 
physical differences. “The 
marvel and wonder became 
stripped from the scientific 
enterprise,” said Thompson. 
“They were emotions associ-
ated with the vulgar masses.” 
Included in the exhibit was 
an 1891 medical text, Human 
Monstrosities. Part of a 
four-volume set with a clas-
sification scheme for vari-
ous human deformities, it 
included a large number of 
stillborn fetuses that were 
either photographed as skel-
etons or dissected specimens.
 An exhibit at the Harvey Cushing/John  
  Hay Whitney Medical Library explores the  
“marvel and wonder” of human abnormalities.
  By Karen Zusi
they remained on display for 
over a century. In 1976 they 
were stored in Norway, and in 
2013 they were finally repa-
triated for burial in Mexico. 
“She's a particularly sad case,” 
said Courtney Thompson, 
M.A. ’12, M.Phil. ’13, Ph.D. ’15. 
“There’s supposed to be a  
level of historical distance, 
but it’s hard not to respond to 
her on an emotional level.”
Two handbills of 
Pastrana’s show appeared 
this year in the Cushing/
Whitney Medical Library’s 
“Teratology: The Science 
and History of Human 
Monstrosity” exhibit, 
curated by Thompson, a 
historian of science and 
medicine; and Melissa Grafe, 
Ph.D., the John R. Bumstead 
Librarian for Medical History.
Teratology, from the 
Greek teras meaning “mon-
ster” or “marvel,” is the 
study of human abnor-
malities. The exhibit focused 
on the changing medical 
In the 19th century, the 
“freak show” also appeared. 
The exhibit included side-
show broadside posters for 
Pastrana, the “Irish Giant,” 
the “Living Skeleton,” and a 
pair of tickets to such side-
shows. The autopsy report 
for Chang and Eng Bunker, 
the original “Siamese twins,” 
was also on display.
The exhibit concluded 
in the 20th century, as the 
medical focus turned from 
morphological classification 
to the underlying causes of 
abnormalities, both genetic 
and environmental. A photo-
graph of a young German girl 
without arms accompanied  
a LIFE magazine photograph 
of Frances O. Kelsey, M.D.,  
Ph.D., the Food and Drug 
Administration scien-
tist who led efforts to ban 
thalidomide, a drug taken 
for morning sickness that 
caused birth defects. Also 
displayed was a scientific 
journal titled Teratology. The 
cover depicted a pregnant 
woman with a red cross over 
her stomach and the words 
“Don’t Get Pregnant,” imply-
ing that environmental factors 
cause too many complications 
during fetal development—at 
least in the authors’ minds. 
The “Teratology” exhibit 
highlighted medicine's ever-
narrower lens, zooming in 
from the outward percep-
tion of “monsters” to the 




TOP LEFT An anonymous 
British printmaker of 
the 19th century made 
this lithograph of two 
conjoined twins, Chang 
and Eng Bunker, who 
lived from 1811 to 1874 
and were known as “The 
Siamese Twins.” At the 
time the lithograph was 
produced, they were 18. 
TOP RIGHT A 19th- 
century poster touted 
both the “curious 
history” of both Julia 
Pastrana, who suffered 
from two undiagnosed 
conditions that gave her 
extreme hair growth 
and thick gums, and  
the “double-bodied 
boy,” a boy with a para-
sitic twin, a rare type  
of conjoined twin.
BOTTOM LEFT A London 
handbill from 1825 
advertised a showing of 
Claude Ambroise Seurat, 
"The Living Skeleton."  
Seurat was born in 
Champagne, France, 
and as he grew, his soft 


































When Jamieson, professor of cell 
biology, arrived at Yale in 1973, 
his task was to launch a cell biol-
ogy department. (He would later 
spend eight years as its chair.) The 
following year he became direc-
tor of Yale’s Medical Scientist 
Training Program, funded by a 
grant from the National Institutes 
of Health and known as the M.D./
Ph.D. program. The physician-
turned-cell-biologist contin-
ued research he’d begun at The 
Rockefeller University under the 
guidance of Nobel laureate George 
Palade, M.D. He studied the 
mechanisms of secretion of pro-
teins by the pancreatic acinar cell 
and other cell types. He closed his 
   Tinker, sailor,  
 Golgi, sly
»
JA M E S D. JA M I E S ON, M.D.,  PH.D., has spent a career dividing his time 
among so many responsibilities—running a lab, directing a program, 
mentoring students, among others—that it’s difficult to know how he found 
time for lunches with students in Marigolds or harbor tours on his sailboat. 
But Jamieson was always available to students in Yale’s M.D./Ph.D. program, 
which he directed for 32 years. “The thing I learned from Jim was the care 
and concern and gentleness with which he treated students,” said Michael 
Caplan, Ph.D. ’87, M.D. ’87, chair and the C. N. H. Long Professor of Cellular 
and Molecular Physiology, and professor of cell biology. Being a mentor, 
Caplan learned from Jamieson, is a large part of being a scientist.
lab in 2001 to devote  
his attention to the M.D./Ph.D. 
program, known more colloqui-
ally as “mud/fud.”
During his tenure some 
300 students graduated from the 
program; and with the recent 
expansion of the program from 
12 to 20 students per year, M.D./
Ph.D. students make up 20 per-
cent of each medical school class. 
“This makes Yale’s program one 
of the largest nationally, reflect-
ing Yale's preeminence in the 
basic and clinical sciences,” 
Jamieson said. In addition, he 
said, electives that he started, 
such as one in translational 
medicine in pediatrics, “ener-
gize and feed positively into the 
med school curriculum.”
Susan J. Baserga, M.D. ’88, 
Ph.D. ’88, noted that Jamieson 
can think critically about 
research design with the same 
ease with which he runs admis-
sion committee meetings. Sam 
B. Sondalle, a fourth-year M.D./
Ph.D. student in her lab, came to 
Yale in part because of Jamieson, 
said Baserga, professor of molecu-
lar biophysics and biochemistry, 
of genetics, and of therapeutic 
radiology. When he met Jamieson 
in December 2010, Sondalle said 
he was struck by Jamieson’s 
friendliness and his generosity in 
offering advice. When Jamieson 
learned about Sondalle’s inter-
est in a rare genetic disease, he 
introduced him to Baserga as a 
potential research advisor. Given 
Baserga’s extensive experience in 
yalemedicine.yale.edu42
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After more than 30 years, 
James Jamieson has 
retired as director of the 
M.D./Ph.D. program. 


















genetics, the match was a perfect 
fi t, Sondalle said.
Caplan described Jamieson 
as down-to-earth and outgo-
ing. “He had an extremely 
paternal—in the best sense of 
the word—connection to the 
program and students,” Caplan 
said, adding that Jamieson had 
a “nitty-gritty, nuts-and-bolts 
understanding of how to do 
experiments.” Jamieson’s lasting 
imprint on the program, Caplan 
said, is his devotion to students.
Barbara Kazmierczak, M.D., 
Ph.D., associate professor of 
medicine, infectious diseases, 
and microbial pathogenesis, who 
became the program’s director 
last year, said she witnessed that 
devotion at a Christmas party at 
Jamieson’s house. Jamieson and 
his wife, Cynthia, stayed up late 
trading movie recommendations 
with a handful of students. “It 
was one of the moments when I 
realized they were embedded in 
the Yale community and really 
loved New Haven, and thought 
of students as family,” she 
said. “He has the curiosity that 
the best scientists have. And it 
extends to curiosity about people, 
motivations, and relationships.” 
Regarding his accomplishments, 
Kazmierczak highlighted a cru-
cial decision that Jamieson made. 
Rather than wait until after they 
fi nish their Ph.D. training to 
begin the required 12 months 
of clinical clerkships, Jamieson 
decreed that M.D./Ph.D. students 
complete half their clerkships 
before beginning their graduate 
study. “With very few exceptions, 
students value this protected 
period of time when they see 
how the book learning trans-
lates into taking care of patients,” 
Kazmierczak said. “For some 
of them, the clerkship period 
informs the thesis they will do.”
Jamieson said he enjoys help-
ing the M.D./Ph.D. students 
blow off steam by offering rides 
in his sailboat or helping out 
with student video parodies for 
the annual Second-Year Show—
for example a spoof on the 
Disney movie Frozen—produced 
by the Class of 2017. Jamieson 
makes a sly cameo appearance in 
the show. Framed on the wall in 
his offi  ce is a photo of Jamieson 
with another class of students 
from earlier days. “For our fear-




A doctor’s love 
affair with medicine 
and literature
For Anna Reisman, M.D., it was a 
summer novel that pointed her to 
a career in medicine. 
As a rising Yale senior and 
English major with no thought 
of becoming a doctor, she read 
Th omas Mann’s classic 1924 novel 
Th e Magic Mountain, a tale of 
tuberculosis patients at a Swiss 
sanatorium. Surprised by her 
own fascination with the disease, 
she went on to read physician-
writers Oliver Sacks, M.D., 
Richard Selzer, M.D., HS ’61, and 
Lewis Th omas, M.D. Soon she 
was a medical student at New 
York University. 
Now an associate professor of 
internal medicine, Reisman (pro-
nounced “Reeseman”) has main-
tained a connection to literature 
that affects how she teaches and 
practices medicine. In essays for 
such publications as Th e Atlantic, 
Slate, and Th e New York Times, 
she has pointed out the prob-
lem with overly dapper doctors, 
defended nurse practitioners who 
want to practice primary care 
without physician oversight, and 
described her own reluctance to 
set foot in a hospice for the fi rst 
time. (Its homey coziness sur-
prised her.) She has even explored 
the troubling ethics of writing 
about patients.
With Lisa Sanders, M.D. ’97, 
HS ’00, associate professor of 
medicine and author of the 
Diagnosis column in Th e New 
York Times Magazine, she co-
directs the Yale Internal Medicine 
Residency Writers’ Workshop. Th e 
workshop guides residents as they 
turn patient care experiences into 
thoughtful narratives. Reisman 
also directs the standardized 
patient program through the 
Teaching and Learning Center and 
plays fl ute with a klezmer group, 
the Nu Haven Kapelye, and the 
Yale Medical Symphony Orchestra.
In March, Reisman became 
the new director of the Yale 
Program for Humanities in 
Medicine, inheriting the post 
from Th omas P. Duffy, M.D. 
Duffy had led the program since 
1999 upon the retirement of 
founding director Howard Spiro, 
Global warming 
aff ects New Haven’s 
poor and elderly. 
A medical school cur-
riculum should integrate 
science and care, allow 
for individual explora-
tion, and develop lifelong 
learners, said a speaker 
at Medical Education Day.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 





System in West Haven (includ-
ing a four-year interlude of  
house calls). The move brought 
them closer to Reisman’s sister 
Lisa, who had just been diag-
nosed with a glioblastoma.  
(Lisa Reisman’s memoir of sur-
viving that tumor, 5 Months 
10 Years 2 Hours, was published 
this spring; she recently deliv-
ered a lecture as part of the 
humanities program.)
People sometimes profess 
surprise when an English major 
chooses a career in medicine. 
But to Reisman, the connection 
between the two fields is obvi-
ous. “More than anything else, 
medicine is about the human 
condition—people, their lives 
and experiences,” she said,  
“and that’s what the humanities 
are about.” 
—Jenny Blair
A novel about tuberculo-
sis patients sparked Anna 
Reisman's interest in 
medicine. She now leads 
the Yale Program for the 
Humanities in Medicine.
M.D., an English major, published 
writer, and tireless advocate for 
intertwining the humanities 
and medicine. What began as a 
lecture series has under Duffy’s 
tenure added a Yale Medical 
Symphony Orchestra and figure 
drawing classes at the School of 
Art. The idea is to provide what 
Duffy calls “an opportunity to 
frolic in all of those realms, to 
keep alive that spirit” of passion 
for the humanities during medi-
cal training. Reisman intends to 
weave humanities right into the 
medical curriculum, exposing 
students to film, literature, and 
visual arts that give the science a 
human context. She also plans to 
create a social media presence for 
the 32-year-old program.
Lectures, poetry readings, 
dancing, drawing, creative writ-
ing, open mics—all pleasant,  
perhaps. But does reading a work 
of literature (or pondering a 
painting) really make students 
better doctors?
“Of course it does!” Reisman 
said. “You read a great novel and 
you really empathize with the 
characters, you get into their 
heads, you see things from their 
perspective. What better train-
ing to be a good doctor than to be 
able to imagine what a patient is 
going through!”
On the lookout for lecturers  
and collaborators across the 
university, Reisman is combing 
places like the School of Drama, 
the Whitney Humanities Center, 
and the Yale Center for British 
Art. “There’s so much stuff going 
on!” she said.
Reisman has the right dispo-
sition for her work, said Geoffrey 
Liu, M.D. ’15, who developed 
a reflective writing workshop 
for third-year medical students 
and worked with Reisman to 
train students to succeed him. 
Reisman, he said, combines an 
easygoing manner with “blunt-
ness and a kind of candor that 
I’ve really come to appreciate.” 
Born at Yale-New Haven 
Hospital and raised in Hamden, 
Reisman earned her English 
degree at Yale. She graduated 
from medical school in 1993, 
then did her residency in pri-
mary care internal medicine at 
NYU Medical Center/Bellevue 
Hospital, staying an extra year 
as chief resident. Then, she and 
medical school classmate Cary 
Gross, M.D., professor of medi-
cine, moved to Baltimore; they 
married in 1998 and returned to 
Connecticut a year later.
Since then, Reisman has 
worked in primary care for the 















Even as a student at New 
Rochelle High School in New 
York, Herbst was interested in 
science. “I knew that I wanted 
to help people, and I always 
thought of medicine as a career.”
He came to Yale as an under-
graduate, leaving in 1984 with 
both bachelor's and master’s 
degrees summa cum laude. 
He earned a Ph.D. from The 
Rockefeller University in 1990 
and an M.D. from Cornell in 1991. 
He completed his residency at 
Brigham and Women’s Hospital 
(BWH) in Boston and fellowships 
in oncology and hematology at 
Dana-Farber Cancer Hospital 
and BWH, and he received a 
master’s degree in clinical inves-
tigation from the Harvard-MIT 
clinical investigator training 
program. He then went on to the 
M.D. Anderson Cancer Center, 
where he led the lung cancer 
section for almost 10 years.
Five years ago he returned  
to the School of Medicine, where 
he had come as a Yale freshman  
to study biophysics and bio-
chemistry. “I studied molecular 
biology and gave my master’s 
thesis defense in the confer-
ence room where we now have 
our developmental therapeutics 
seminar once a month,” he said.  
“The blackboard looks exactly 
the same.”
  How Roy Herbst  
became a media go-to 
guy on immunotherapy




W H E N T H E A M E R IC A N S O C I E T Y OF C L I N IC A L ONC OL O GY 
met in Chicago this spring, one of the hottest topics was the 
promise of immunotherapy against cancer. And one of the 
point men for the media was Roy S. Herbst, M.S. ’84, Ph.D., 
M.D., chief of medical oncology at Smilow Cancer Hospital, 
associate director for translational research, and Ensign 
Professor of Medicine, who appeared on CNN, Fox News, 
and in newspapers from as far away as South Africa and the 
United Kingdom. He has spent more than 20 years both in 
the lab, studying the underlying science of cancer, and in 
the clinic, bringing novel treatments to patients. He shares 
his colleagues’ excitement about immunotherapy, which 
harnesses the body’s immune system to fight tumors. 
Why did you choose to devote 
your career to oncology?  
At Cornell and Rockefeller, 
I was interested in science 
and medicine, and cancer 
seemed like an area where 
you could bring science to 
bear on difficult problems. 
In my second year of med 
school, my mother devel-
oped breast cancer. I remem-
ber taking her slides to the 
pathology group to confirm 
her diagnosis and exploring 
treatment options with my 
professors and mentor. This 
seemed like a natural area 
for me because of the pathol-
ogy, the science, and the new 
therapies that were evolving. 
You could bring together the 
science and the caring for 
people all in one career.
Do you see yourself as a  
clinician or a scientist?  
I see myself as someone who is 
looking to the lab for new ideas 
and new drugs, while serving 
on the front line of the clinical 
translation. I want to develop 
drugs that are safer and more 
effective for cancer patients by 
understanding why they work 
or why they don’t work. Every 
Tuesday I see patients at the 
Smilow hospital in the lung 
clinic, which I lead, and seek 
to implement the most novel 
protocol-driven care. I also 
maintain a small lab where 
we’re doing some basic trans-
lational studies, but we mostly 
collaborate with some of the 
top labs at Yale and elsewhere.
   How Roy Herbst  
 became a media go-to  
  guy on immunotherapy





What is your role at Yale?  
My primary goal is to make 
sure that medical oncol-
ogy offers state-of-the-art 
care while building a grant-
funded research program. 
As the chief of medical 
oncology I lead an ever-
expanding group of medical 
oncologists with a robust 
clinical service. As the asso-
ciate cancer center director 
for translational research, 
my team and I are work-
ing to enhance and build 
a grants infrastructure to 
do more to bring scientists 
into the study of cancer. We 
want to get more people 
working together on the 
common problem of how to 
better treat someone with 
an incurable cancer. There 
is so much expertise at Yale 
in basic science and clini-
cal care, but the real trick 
is to get everyone working 
together to combat human 
disease. My real goal is not 
just the lung program. I 
need to see every program 
in the cancer center succeed 
in the same way.
Why has immunotherapy 
emerged as such a break-
through? What better than 
the specificity, memory, and 
adaptability of one’s own 
immune system to attack a 
cancer?  It really is the iden-
tification of the immune 
immunopathology, sequenc-
ing tumors to understand 
what it is about those that 
respond versus those that 
don’t respond. The tumor 
can, unfortunately, learn 
how to become resistant. 
The immune system has 
memory; and hopefully, 
as the tumor adapts, the 
immune system also adapts. 
In some cases this does not 
occur and hence we are 
developing even more new 
combinations among tar-
geted therapies, vaccines, 
and other immunotherapies.
How did you become one 
of the public faces of ASCO? 
Our medical oncology sec-
tion, led by Mario Sznol, 
Harriet Kluger, and Scott 
Gettinger, did some of the 
earliest immunotherapy 
studies for cancer. I led one 
of the earliest Phase 1 trials 
in immunotherapy, which 
was published in Nature last 
year. Since my work has been 
focusing on both the clinic 
and the science. I’m able to 
talk not just about the clini-
cal results, but also about the 
science behind the results. 
And what good is your work 
if you can’t make people real-
ize what you’re doing to help 
patients, to obtain grants, to 
encourage philanthropy and 
encourage other researchers 
to work with you?
checkpoint PDL1 and the 
establishment of PD1/PDL1 
inhibitors that have changed 
the field. You have these 
tumors, and you would hope 
that the immune system’s 
T cells would recognize 
the tumor as foreign. But 
the tumor makes a protein, 
PDL1, which camouflages 
the tumor, making it invis-
ible. The new therapies are 
trying to knock down that 
PDL1. A lot of this work, by 
the way, comes from the 
studies of Lieping Chen 
here at Yale. Patients with 
lung cancer who previously 
would succumb to their dis-
ease within a year are now 
alive at two, three years or 
more. We are seeing tumors 
shrink more than 20 percent 
of the time in lung cancer, 
25 percent of the time in 
melanoma, and 15 percent 
of the time in renal cancer. 
These agents are benefit-
ing people, but it’s not a 
home run. Only 20 to 25 
percent of patients benefit. 
We clearly have to do better, 
and current work is aimed 
at identifying biomarkers of 
response and resistance so 
we can develop even more 
effective combinations.
What are the next steps?  
One of our big initiatives 
at Yale is to collect tumor 
samples from patients who 
have responded to immuno-
therapy and from those who 















{To nominate a subject for Q&A, contactYale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
 A sense of  
community for people 
with mental illnesses
Citizenship and Mental 
Health began when a man 
who’d once been homeless 
said that he wanted to give 
up his apartment and return 
to the streets of New Haven.
Jim, said sociologist 
Michael Rowe, Ph.D. ’96, was 
a veteran who heard voices. 
He had initially resisted the 
overtures of a peer outreach 
worker who gradually won 
his trust, convinced him 
to get treatment for his ill-
ness, and helped him find 
an apartment. “Jim was the 
quintessential success story 
of outreach,” said Rowe, an 
associate professor of psy-
chiatry and co-director of the 
Yale Program for Recovery 
and Community Health. 
And then, one day,  
“his outreach worker came 
into our team meeting and 
said ‘Jim wants to live out 
on the street again,’ ” said 
Rowe. Team members were 
incredulous: why would Jim 
want to return to the pave-
ment under the Water Street 
overpass? The outreach 
worker explained, “Because 
there he knew people. He 
felt that he belonged.” Rowe 
recalled: “That was a heart-
breaking moment that 
revealed to me the limita-
tions of what we were doing.”
That day in the mid-1990s 
led Rowe to launch what 
would become the Citizens 
Collaborative. Its aim was to 
integrate people with mental 
illness into communities 
beyond those created by the 
mental health system. “Even 
the most innovative mental 
health programs, in which 
work was more than work, 
went beyond the clock, and 
even smashed the damned 
clock, could not make 
people neighbors, commu-
nity members, and citizens,” 
Rowe wrote. He envisioned 
people with mental illness 
walking down streets to 
greetings from neighbors 
and invitations to join in 
a neighborhood clean-up 
or take part in discussions 
about upcoming elections.
Rowe and colleagues 
created and studied citi-
zenship programs in New 
Haven, funded by the 
National Institute of Mental 
Health, the Connecticut 
Department of Mental Health 
and Addiction Services, and 
the Melville Charitable Trust. 
They registered people to 
vote; helped clients con-
nect with people who shared 
their interests, such as fellow 
cycling enthusiasts or stock 
traders; and encouraged 
clients to help others, for 
example, by serving on an 
advisory board.
Citizenship, as the team 
came to define it, comprises 
rights like freedom from 
stigma, responsibilities like 
knowing how to manage 
money, roles as parents or 
employees, resources like 
housing and religious com-
munities, and relationships 
with others. 
A randomized controlled 
study of 114 people who 
received mental health ser-
vices showed that those who 
participated in a citizenship 
program were more satisfied 
with their lives and less apt 
to misuse alcohol and drugs.
This need to foster citizen-
ship, said Rowe, is rooted in 
the deinstitutionalization of 
the 1960s and “came out of 
the success of mental health 
outreach work—reaching its 
limit and hitting the wall.” To 
thrive, people with mental ill-
ness need more than just ser-
vices, said Rowe. They need to 
“come in from the margins.”
A guide for setting up citizenship 
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book review
T H I R D-Y E A R S T U DE N T S beginning their clinical clerkships took to the new Yale Center for 
Medical Simulation on June 15 to practice clinical skills best learned on a manikin instead 
of a live patient. At the expanded center, which opened in January, they used bag-valve 
masks for manual ventilation and inserted catheters and nasogastric tubes into the practice 
manikins. “Our patients today are cooperative for you,” joked Leigh V. Evans, M.D., 
director of health care simulation. In addition to learning technical procedures, clerkship 
students have the opportunity to lead medical teams in simulated case studies based on 
real patients. “It’s active learning, it's feedback, and they get to practice,” said Evans. 
—Karen Zusi
Th e most cooperative of patients
Send notices of new books to
Yale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
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